Drugs / CD4-IgG
CD4-IgG
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT00000675 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000663 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000642 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000976 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002250 | — | HIV infectious disease, autoimmune thrombocytopenic purpura | Genentech, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00000647 | ? → Dec 1994 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD4-IgG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000647 ↗ |
| Known as | rCD4-IgG | “To determine both the safety, tolerance, and pharmacokinetic profile (blood levels) of recombinant CD4 immunoglobulin G (rCD4-IgG) by intravenous bolus administration (given...” NCT00000642 ↗2“recombinant human CD4 immunoglobulin (rCd4-IgG)” NCT00000675 ↗ “Recombinant CD4 Immunoglobulin G (rCD4-IgG)” NCT00000663 ↗ |
| Known as | rCD4-lgG | “A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura” NCT00002250 ↗ |
| Known as | recombinant CD4 immunoglobulin G | “To determine both the safety, tolerance, and pharmacokinetic profile (blood levels) of recombinant CD4 immunoglobulin G (rCD4-IgG) by intravenous bolus administration (given...” NCT00000642 ↗ |
| Known as | recombinant human CD4 immunoglobulin | “recombinant human CD4 immunoglobulin (rCd4-IgG)” NCT00000675 ↗ |
| Known as | recombinant human CD4-immunoglobulin G | “recombinant human CD4-immunoglobulin G (CD4-IgG) and zidovudine (AZT) combination therapy” NCT00000976 ↗ |
| Action | Inhibit | “CD4-IgG is capable of binding to HIV envelope protein (gp120) and inhibiting HIV infectivity in test tube studies.” NCT00000976 ↗ |
| Modality | Protein / enzyme biologic | “recombinant CD4 immunoglobulin G” NCT00000642 ↗ |
| Route | Intravenous | “by intravenous bolus administration” NCT00000642 ↗ |